The American Council of the Blind (ACB) has announced that the Website and Software Applications Accessibility Act has once again been introduced in the House of Representatives on Wednesday, May 14. This was a wonderful way to usher in Global Accessibility Awareness Day (GAAD) on Thursday, May 15. The bill was introduced by Republican Congressman [Read More]
Neurotech Pharmaceuticals, Inc. has announced FDA approval of ENCELTO (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel). ENCELTO is the First and Only FDA-approved first and only treatment for MacTel. MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly impacting patients’ quality of [Read More]
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo may help people with DME maintain their vision Approval marks the second indication for Susvimo in addition to wet, or neovascular age-related macular [Read More]